Printer Friendly

THE IMMUNE RESPONSE CORP. CONFIRMS SCHEDULE FOR COMPLETION OF PHASE II/III CLINICAL TRIAL IN 1992

 THE IMMUNE RESPONSE CORP. CONFIRMS SCHEDULE
 FOR COMPLETION OF PHASE II/III CLINICAL TRIAL IN 1992
 SAN DIEGO, March 7 /PRNewswire/ -- The Immune Response Corp. (NASDAQ-NMS: IMNR) announced today that a phase II/III clinical trial of the company's HIV therapeutic vaccine is on schedule for completion in September 1992, as previously announced.
 The phase II/III trial is being sponsored by a joint venture between Immune Response and Rhone-Poulenc Rorer Inc. This trial is a double- blind, placebo-controlled efficacy study measuring the effect of treatment with the HIV therapeutic vaccine on 103 HIV-infected patients in the early asymptomatic stages of this infection. The primary objective of the current phase II/III clinical trial is to provide the data necessary to support a Product License Application planned for 1993 and to secure Food and Drug Administration approval for commercial marketing of the HIV therapeutic vaccine.
 "We are pleased with the progress of our clinical trials for the HIV therapeutic vaccine. The principal initial application of the HIV therapeutic vaccine, if successfully developed, will be to prevent or delay the development of AIDS in HIV-infected individuals," said James B. Glavin, president and chief executive officer of The Immune Response Corp.
 An article in the March 6, 1992 issue of The Wall Street Journal that referred to the status of a planned study in uninfected volunteers has inadvertently created confusion about the company's clinical trials. The development status of a preventive vaccine for individuals not infected with HIV is unrelated to the current trials on the HIV therapeutic vaccine, which is intended only for already-infected patients.
 The Immune Response Corp. is a biopharmaceutical company engaged in the development of proprietary products for the treatment of HIV infection, which leads to AIDS and for the treatment of certain autoimmune diseases, particularly rheumatoid arthritis, multiple sclerosis and insulin-dependent diabetes.
 -0- 3/7/92
 /CONTACT: Steven Basta of Immune Response, 619-431-7080/
 (IMNR) CO: The Immune Response Corp. ST: California IN: MTC SU: PDT


KJ-EH -- SDSA1 -- 6121 03/07/92 08:00 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 7, 1992
Words:337
Previous Article:DOLLY PARTON TO WELCOME BURT REYNOLDS AND REBA McENTIRE TO DOLLYWOOD'S 7TH GRAND OPENING APRIL 25-26, 1992
Next Article:NEW DETROIT BOARD ACTS ON SEVERAL PROPOSALS AT MARCH MEETING
Topics:


Related Articles
THE IMMUNE RESPONSE CORP. ANNOUNCES THIRD QUARTER 1991 FINANCIAL RESULTS
THE IMMUNE RESPONSE CORPORATION COMMENTS ON INTEREST IN PROGRESS ON HIV THERAPEUTIC VACCINE
IMMUNE RESPONSE FILES INVESTIGATIONAL NEW DRUG APPLICATION FOR NEW RHEUMATOID ARTHRITIS TREATMENT
THE IMMUNE RESPONSE CORP., RHONE-POULENC RORER INC. AND PASTEUR MERIEUX CONNAUGHT GROUP ANNOUNCE DISCUSSIONS ON HIV MANUFACTURING JOINT VENTURE
THE IMMUNE RESPONSE CORPORATION ANNOUNCES FOURTH QUARTER AND YEAR-END 1991 FINANCIAL RESULTS
THE IMMUNE RESPONSE CORPORATION ANNOUNCES SECOND QUARTER 1993 FINANCIAL RESULTS
THE IMMUNE RESPONSE CORPORATION ANNOUNCES PUBLICATION OF RESULTS FROM PHASE II DOSE-RANGING CLINICAL TRAIL OF HIV IMMUNOTHERAPEUTIC

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters